Celldex Therapeutics (CLDX) Net Cash Flow (2010 - 2026)

Celldex Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 161.02% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $18.6 million (up 118.97% YoY), while the FY2025 annual figure was $515000.0, up 107.97% from the prior year.
• Net Cash Flow was $6.8 million for Q1 2026 at Celldex Therapeutics, up from -$7.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $80.3 million in Q1 2024 to a low of -$72.3 million in Q2 2024.
• Historically, Net Cash Flow has averaged -$201529.4 across 5 years, with a median of -$6.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow sank 933.3% in 2023, then jumped 305.3% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $10.8 million in 2022, then gained by 26.13% to $13.7 million in 2023, then slumped by 158.79% to -$8.0 million in 2024, then advanced by 10.9% to -$7.2 million in 2025, then soared by 195.53% to $6.8 million in 2026.
• The last three Net Cash Flow figures came in at $6.8 million (Q1 2026), -$7.2 million (Q4 2025), and $13.0 million (Q3 2025), per Business Quant data.